peroxisome proliferator activated receptors

Summary

Summary: TRANSCRIPTION FACTORS that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes.

Top Publications

  1. ncbi An overview on biological mechanisms of PPARs
    Bhavani Prasad Kota
    Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
    Pharmacol Res 51:85-94. 2005
  2. ncbi Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet
    Tatsuya Nagasawa
    Toxicology Research Laboratory, R and D, Kissei Pharmaceutical Co, Ltd, 2320 1 Maki, Hotaka, Azumino City, Nagano Pref, 399 8305, Japan
    Eur J Pharmacol 536:182-91. 2006
  3. ncbi Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors
    Jeong Ho Kim
    Department of Pathobiology, University of Tennessee, Knoxville, Tennessee 37996, USA
    Toxicol Sci 85:585-93. 2005
  4. ncbi International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
    Liliane Michalik
    Center for Integrative Genomics, National Research Centre Frontiers in Genetics, University of Lausanne, Lausanne, Switzerland
    Pharmacol Rev 58:726-41. 2006
  5. ncbi PPARs as drug targets to modulate inflammatory responses?
    Raphael Genolet
    Center for Integrative Genomics, NCCR Frontiers in Genomics, University of Lausanne, CH 1015 Lausanne, Switzerland
    Curr Drug Targets Inflamm Allergy 3:361-75. 2004
  6. ncbi PPARs: therapeutic targets for metabolic disease
    Joel P Berger
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA
    Trends Pharmacol Sci 26:244-51. 2005
  7. ncbi Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators
    Vincent Zoete
    Swiss Institute of Bioinformatics SIB, Quartier Sorge, Batiment Genopode, CH 1015 Lausanne, Switzerland
    Biochim Biophys Acta 1771:915-25. 2007
  8. ncbi PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
    Andrew C Li
    Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    J Lipid Res 45:2161-73. 2004
  9. ncbi From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
    Jerome N Feige
    Center for Integrative Genomics, NCCR Frontiers in Genetics, Le Génopode, University of Lausanne, CH 1015 Lausanne, Switzerland
    Prog Lipid Res 45:120-59. 2006
  10. ncbi Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes
    Nguan Soon Tan
    Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, Biology Building, CH 1015 Lausanne, Switzerland
    J Steroid Biochem Mol Biol 93:99-105. 2005

Detail Information

Publications242 found, 100 shown here

  1. ncbi An overview on biological mechanisms of PPARs
    Bhavani Prasad Kota
    Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
    Pharmacol Res 51:85-94. 2005
    b>Peroxisome proliferator activated receptors (PPARs) are transcriptional factors belonging to the ligand-activated nuclear receptor superfamily. They are ubiquitously expressed throughout the body...
  2. ncbi Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet
    Tatsuya Nagasawa
    Toxicology Research Laboratory, R and D, Kissei Pharmaceutical Co, Ltd, 2320 1 Maki, Hotaka, Azumino City, Nagano Pref, 399 8305, Japan
    Eur J Pharmacol 536:182-91. 2006
    ....
  3. ncbi Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors
    Jeong Ho Kim
    Department of Pathobiology, University of Tennessee, Knoxville, Tennessee 37996, USA
    Toxicol Sci 85:585-93. 2005
    ..In conclusion, PAHs activate PPAR alpha and PPAR beta/delta, and up-regulate EGR-1 expression in vitro as well as in vivo. These data may provide a diversity of PAH activity in several biological pathways...
  4. ncbi International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
    Liliane Michalik
    Center for Integrative Genomics, National Research Centre Frontiers in Genetics, University of Lausanne, Lausanne, Switzerland
    Pharmacol Rev 58:726-41. 2006
    ..Thus, selective action of PPARs in vivo results from the interplay at a given time point between expression levels of each of the three PPAR and RXR isotypes, affinity for a specific promoter PPRE, and ligand and cofactor availabilities...
  5. ncbi PPARs as drug targets to modulate inflammatory responses?
    Raphael Genolet
    Center for Integrative Genomics, NCCR Frontiers in Genomics, University of Lausanne, CH 1015 Lausanne, Switzerland
    Curr Drug Targets Inflamm Allergy 3:361-75. 2004
    ..We also discuss the potential utilisation of PPAR specific ligands in the treatment of inflammatory diseases, such as inflammatory bowel diseases, atherosclerosis, Parkinson's and Alzheimer's diseases...
  6. ncbi PPARs: therapeutic targets for metabolic disease
    Joel P Berger
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA
    Trends Pharmacol Sci 26:244-51. 2005
    ..Novel PPAR ligands are now being developed that possess broader efficacies and improved tolerability compared with currently available therapeutic agents...
  7. ncbi Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators
    Vincent Zoete
    Swiss Institute of Bioinformatics SIB, Quartier Sorge, Batiment Genopode, CH 1015 Lausanne, Switzerland
    Biochim Biophys Acta 1771:915-25. 2007
    ..Finally, the interactions of PPARs LBD with co-activators or co-repressors, as well as with the retinoid X receptor (RXR) are described and considered in relation to PPARs activation...
  8. ncbi PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
    Andrew C Li
    Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    J Lipid Res 45:2161-73. 2004
    ..Here, we review recent studies that provide new insights into the mechanisms by which these subclasses of nuclear receptors act to systemically influence lipid and glucose metabolism and regulate gene expression within the artery wall...
  9. ncbi From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
    Jerome N Feige
    Center for Integrative Genomics, NCCR Frontiers in Genetics, Le Génopode, University of Lausanne, CH 1015 Lausanne, Switzerland
    Prog Lipid Res 45:120-59. 2006
    ..Finally, we discuss how the integration of various intra-cellular signaling pathways allows PPARs to participate to whole-body homeostasis by mediating regulatory crosstalks between organs...
  10. ncbi Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes
    Nguan Soon Tan
    Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, Biology Building, CH 1015 Lausanne, Switzerland
    J Steroid Biochem Mol Biol 93:99-105. 2005
    ..It is also becoming apparent that understanding the regulation of PPAR expression and activity, can itself have a significant influence on how the expression of subgroups of target genes is studied and integrated in current knowledge...
  11. ncbi Be fit or be sick: peroxisome proliferator-activated receptors are down the road
    Beatrice Desvergne
    Center for Integrative Genomics, University of Lausanne, Biology Building, CH 1015 Lausanne Dorigny, Switzerland
    Mol Endocrinol 18:1321-32. 2004
    ..This review presents a summary of the recent findings on their dual involvement in health and disease...
  12. ncbi Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand
    Jerome N Feige
    Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, CH 1015 Lausanne, Switzerland
    J Biol Chem 280:17880-90. 2005
    ....
  13. ncbi Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin
    Elzbieta M Kurowska
    KGK Synergize Inc, Research and Development Division, London, Ontario, Canada N6A 5R8
    Lipids 39:143-51. 2004
    ..control). The data suggest that tangeretin modulates apoB-containing lipoprotein metabolism through multiple mechanisms...
  14. ncbi Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet
    Caroline Fernandes-Santos
    Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Brazil
    Nutrition 25:818-27. 2009
    ....
  15. ncbi Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives
    P A Grimaldi
    Inserm U636, Centre de Biochimie, UFR Sciences, Universite de Nice Sophia Antipolis, Parc Valrose, 06108, Nice, France
    Cell Mol Life Sci 64:2459-64. 2007
    ....
  16. ncbi Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Tel Hashomer, Israel
    Arch Intern Med 166:737-41. 2006
    ..The present analysis aimed to investigate the effect of bezafibrate on IR in patients with coronary artery disease enrolled in the Bezafibrate Infarction Prevention Study...
  17. pmc Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Sheba Medical Center, 52621 Tel Hashomer, Israel
    Cardiovasc Diabetol 4:14. 2005
    ..More powerful new compounds with pan-PPAR activity and proven long-term safety should be highly effective in a clinical setting of patients with coexisting relevant lipid and glucose metabolism disorders...
  18. ncbi Kinase signaling cascades that modulate peroxisome proliferator-activated receptors
    Laurent Gelman
    Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, Switzerland
    Curr Opin Cell Biol 17:216-22. 2005
    ..The study of this dual regulation mode, which allows PPARs to integrate signals conveyed by lipophilic ligands with those coming from the plasma membrane, may ultimately offer new therapeutic strategies...
  19. ncbi Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma
    Tae Young Na
    College of Pharmacy, Seoul National University, Seoul, Korea
    Hepatology 49:1122-31. 2009
    ..036), SREBP-1c (P = 0.008), FAS, and stearoyl-coenyzme A desaturase-1 (P = 0.001) in hepatocellular carcinoma (HCC) in comparison with adjacent nontumorous nodules in human HBV-associated HCC specimens...
  20. ncbi Molecular mechanisms of cross-talk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart
    Outi M Hyyti
    Division of Cardiology, Department of Pediatrics, Childrens Hospital and Regional Medical Center, 4800 Sandpoint Way NE, 4G 1, Seattle, WA 98105, USA
    Cardiovasc Drugs Ther 20:463-9. 2006
    Thyroid hormone receptors (TR) and peroxisome proliferator activated receptors (PPAR) regulate cardiac metabolism...
  21. ncbi Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy
    Reeba K Vikramadithyan
    Department of Medicine, Columbia University, New York, NY 10032, USA
    J Pharmacol Exp Ther 313:586-93. 2005
    ..These changes were paralleled by alterations in heart lipid uptake. Overall, PPAR activators exhibit differential effects in this model of lipotoxic dilated cardiomyopathy...
  22. ncbi A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein
    Paul Targett-Adams
    MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, UK
    Biochim Biophys Acta 1728:95-104. 2005
    ..These findings offer insight into the mechanisms which serve to regulate ADRP transcription and intracellular lipid storage...
  23. ncbi Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas
    Mads Wichmann Matthiessen
    Department of Medical Gastroenterology C112, Herlev University Hospital, 2730 Herlev, Denmark
    Scand J Gastroenterol 40:198-205. 2005
    ..The aim of this study was to determine PPAR expression and function in normal human colonic epithelial cells and tubular adenomas...
  24. ncbi PPAR agonists modulate human osteoclast formation and activity in vitro
    B Y Chan
    Department of Clinical Biochemistry, Royal Liverpool University Hospital, The University of Liverpool, Liverpool, L69 3GA, UK
    Bone 40:149-59. 2007
    ..In conclusion, this study highlights the potential of PPARs as therapeutic targets in diseases with accelerated osteoclast formation and resorption...
  25. ncbi Safety issues and prospects for future generations of PPAR modulators
    Anne Rubenstrunk
    GENFIT, F 59006 Loos, France
    Biochim Biophys Acta 1771:1065-81. 2007
    ..The selective modulation of PPAR activities is a promising approach to develop new drugs with preserved efficacy but diminished adverse effects...
  26. ncbi Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
    Jonathan D Brown
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass, USA
    Circulation 115:518-33. 2007
    ..Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology...
  27. ncbi Polyunsaturated fatty acid regulation of genes of lipid metabolism
    Harini Sampath
    Department of Nutritional Sciences, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    Annu Rev Nutr 25:317-40. 2005
    ..Working out the mechanisms by which these interactions and consequent effects occur is proving to be complicated but is invaluable to our understanding of the role that dietary fat can play in disease management and prevention...
  28. ncbi Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics
    Danielle G Lemay
    United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, and Department of Nutrition, University of California Davis, 95616, USA
    J Lipid Res 47:1583-7. 2006
    ..g., chromatin remodeling, DNA damage response, Wnt, and mitogen-activated protein kinase signaling). This first genome-wide library of high-confidence predicted PPAR target genes will be a valuable resource to PPAR biologists...
  29. ncbi Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands
    Mathieu Seimandi
    INSERM Unité 540, Endocrinologie Moléculaire et Cellulaire des Cancers, 60 rue de Navacelles, 34090 Montpellier, France
    Anal Biochem 344:8-15. 2005
    ..We conclude that our stable models allow specific and sensitive measurement of PPAR ligand activities and are a high-throughput, cell-based screening tool for identifying and characterizing PPAR ligands...
  30. ncbi Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2
    Cheryl E Rockwell
    Department of Pharmacology and Toxicology, Michigan State University, 315 National Food Safety and Toxicology Building, East Lansing, MI 48824 1317, USA
    Mol Pharmacol 70:101-11. 2006
    ..Together, the aforementioned studies identify PPARgamma as a novel intracellular target of 2-AG, which mediates the suppression of IL-2 by 2-AG in a manner that is independent of CB1 and/or CB2...
  31. ncbi Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Bart Staels
    Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Diabetes 54:2460-70. 2005
    ..The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation...
  32. ncbi Identification and organ expression of peroxisome proliferator activated receptors in brown trout (Salmo trutta f. fario)
    Carla Batista-Pinto
    Laboratory of Cell Biology, ICBAS Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal
    Biochim Biophys Acta 1731:88-94. 2005
    Although widely studied in mammals, little information about fish peroxisome proliferator activated receptors (PPARs) is yet available...
  33. ncbi Evolution of peroxisome proliferator-activated receptor agonists
    Feng Chang
    Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    Ann Pharmacother 41:973-83. 2007
    ..To discuss the evolution of peroxisome proliferator-activated receptor (PPAR) agonists from single site to multiple subtype or partial agonists for the treatment of type 2 diabetes, dyslipidemia, obesity, and the metabolic syndrome...
  34. ncbi The human semaphorin 6B gene is down regulated by PPARs
    Philippe Collet
    EA 3446 Peroxisome Proliferators, Faculty of Sciences, BP 239, University Henri Poincaré Nancy 1, 54506 Vandoeuvre les Nancy, France
    Genomics 83:1141-50. 2004
    ..In addition, cross talk between the peroxisome proliferator and retinoic acid pathways is suggested...
  35. ncbi The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors
    Tatjana Degenhardt
    Department of Biochemistry and A I Virtanen Institute, University of Kuopio, FIN 70211 Kuopio, Finland
    J Biol Chem 281:39607-19. 2006
    ..We also show that these additional PPAR binding genes contain a number of candidate PPREs and that their mRNA levels respond quickly to the presence of PPAR ligands, indicating that they are also primary PPAR target genes...
  36. pmc Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors
    S E O'Sullivan
    School of Biomedical Sciences, University of Notttingham, Queen s Medical Center, Nottingham, UK
    Br J Pharmacol 152:576-82. 2007
    ....
  37. pmc Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands
    Hiroyuki Kohno
    Department of Oncologic Pathology, Kanazawa Medical University, Uchinada, Ishikawa 920 0293, Japan
    BMC Cancer 5:46. 2005
    ....
  38. ncbi The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol
    Stephen Nicholls
    Heart Research Institute, Sydney, Australia
    Semin Vasc Med 4:187-95. 2004
    ..As such, these factors have become important targets in the development of effective strategies to prevent atherosclerotic cardiovascular disease...
  39. ncbi Preventing the progression of diabetes mellitus
    Brian V Reamy
    Am Fam Physician 71:425. 2005
  40. ncbi Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism
    David Moulin
    UMR 7561 CNRS Université Henri Poincaré Nancy 1, Vandoeuvre les Nancy, France
    Arthritis Rheum 52:759-69. 2005
    ....
  41. ncbi Phosphorylation of PPARs: from molecular characterization to physiological relevance
    Claire Diradourian
    Departement d Endocrinologie, Institut Cochin, INSERM U567 CNRS UMR8104, Universite Paris V, 24, rue du Faubourg Saint Jacques 75014 Paris, France
    Biochimie 87:33-8. 2005
    ..Molecular consequences are multiple, including changes in ligand affinity, DNA binding, recruitment of transcriptional cofactors, proteasome degradation... Finally, the physiological relevance of PPAR phosphorylation is discussed...
  42. ncbi PPARs and other nuclear receptors in inflammation
    Giovanni Rizzo
    Department of Internal Medicine, University of Perugia, Via E dal Pozzo, 06122 Perugia, Italy
    Curr Opin Pharmacol 6:421-7. 2006
    ..In addition, peroxisome proliferator-activated receptors and liverXreceptors, in response to endogenous eicosanoids and oxysterols, respectively, modulate transcriptional pathways involved in inflammatory responses and lipid homeostasis...
  43. pmc Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis
    Michael K Racke
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, 75390, USA
    J Nutr 136:700-3. 2006
    ..The fact that PPARalpha agonists have been used as therapeutic agents in humans to treat metabolic conditions for over 25 years with little toxicity makes them attractive candidates for use as adjunctive therapies in MS...
  44. ncbi Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma
    Avery August
    Center for Molecular Immunology and Infectious Disease, The Pennsylvania State University, University Park, 16802, USA
    J Nutr 136:695-9. 2006
    ..In vitro, T cells from ciglitazone-treated mice secreted significantly less IL-4 and IFN-gamma in response to restimulation. These data suggest that PPARgamma agonists may be useful for the treatment of allergic asthma...
  45. ncbi Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands
    M A Jakobsen
    Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
    Scand J Immunol 63:330-7. 2006
    ..Our data suggest that naturally occurring PPAR ligands like fatty acids and fatty acid derivates have anti-inflammatory effects by redirecting DC into a less stimulatory mode...
  46. ncbi Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity
    Grant D Barish
    Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    J Nutr 136:690-4. 2006
    ....
  47. ncbi Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac deve
    Michael Steinmetz
    Department of Pediatric Cardiology and Intensive Care Medicine, Georg August University Gottingen, Robert Koch Str 40, 37075 Gottingen, Germany
    Basic Res Cardiol 100:263-9. 2005
    ..The aim of this study was to investigate the changes in mRNA expression levels of genes involved in the control of cardiac fatty acid metabolism in the transition from neonatal to adult life...
  48. ncbi Caloric restriction results in decreased expression of peroxisome proliferator-activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice
    Michal M Masternak
    Department of Internal Medicine, Geriatrics Research, Southern Illnois University School of Medicine, Springfield, 62794 9628, USA
    J Gerontol A Biol Sci Med Sci 60:1238-45. 2005
    ..This suggested metabolic change clearly does not affect whole-body insulin action. These findings suggest that whole-animal insulin sensitivity is not regulated through skeletal muscle insulin action...
  49. ncbi Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia
    W H Yin
    Division of Cardiology, Department of Internal Medicine, Cheng Hsin General Hospital, and Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming University, School of Medicine, Taipei, Taiwan
    Diabetes Metab 32:229-35. 2006
    ..We hypothesized that the combination of TZD+fibrate may be better than the sulfonylurea + statin approach regarding modifying the adipokine profile in diabetic patients with dyslipidemia...
  50. ncbi Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents
    James R Henry
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 16:6293-7. 2006
    ..Novel tetrahydroisoquinolines have been developed as potent PPAR ligands. Evaluation of these compounds in PPARgamma responsive models of type 2 diabetes is described...
  51. ncbi Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate
    Margy L Takacs
    Reproductive Toxicology Division, National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
    Toxicol Sci 95:108-17. 2007
    ....
  52. ncbi [PPAR family and its relationship to metabolic syndrome]
    Xiao Yan Zhang
    Peking University Diabetes Center, Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing 100083
    Sheng Li Ke Xue Jin Zhan 36:6-12. 2005
    ..Particular emphasis is placed on their pathogenic roles in the metabolic syndrome and the therapeutic utility of PPAR modulators in the treatment of type II diabetes...
  53. pmc Gaining weight: the Keystone Symposium on PPAR and LXR
    Michael Lehrke
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Genes Dev 19:1737-42. 2005
    ..In recognition of this, a recent Keystone Symposium was devoted to these metabolic receptors. Here, we summarize some of the major highlights and future projections discussed at the meeting...
  54. ncbi PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor
    Michelle N Emery
    Department of Endocrinology, St Bartholomew s and the Royal London School of Medicine and Dentistry, London, UK
    Clin Endocrinol (Oxf) 65:389-95. 2006
    ..However, the mechanisms for the responsivity to rosiglitazone have remained unclear...
  55. ncbi LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes
    Yan J Jiang
    Department of Medicine, University of California San Francisco, San Francisco, CA 94121, USA
    J Lipid Res 46:2657-66. 2005
    ..Thus, LXR and PPAR activators regulate the expression of SULT2B1b, the key enzyme in the synthesis of CS, which is a potent regulator of epidermal differentiation and corneocyte desquamation...
  56. ncbi [Peroxisome proliferator activated receptor ligands and angiogenesis]
    Mayumi Sato
    Medical R and D Center, Tokyo Metropolitan Institute for Medical Science
    Nihon Rinsho 63:603-8. 2005
    ..In this review, I highlight data concerning PPARs ligands involved in the biological mechanisms underlying antiangiogenesis...
  57. ncbi Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors
    Markus Neumeier
    Department of Internal Medicine I, University of Regensburg, D 93042 Regensburg, Germany
    Biochem Biophys Res Commun 334:924-9. 2005
    ..Elevated AdipoR1 induced by hepatotoxic troglitazone may indicate a role of this receptor in adiponectin-mediated beneficial effects in liver damage...
  58. ncbi Rational drug design and PPAR agonists
    Riccardo Perfetti
    Department of Medical Sciences, Amgen Inc, One Amgen Center Drive, Mail Stop 38 3 A, Thousand Oaks, CA 91320 1799, USA
    Curr Diab Rep 5:340-5. 2005
    ....
  59. ncbi [Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects]
    S Dharancy
    INSERM U795, Boulevard du Professeur Jules Leclercq, 59037 Lille, France
    Gastroenterol Clin Biol 32:339-50. 2008
    ..In terms of therapy, animal studies and human trials have been conducted in steatopathies. However, clinicians have to be aware of potential specific side effects related to glitazones especially on cardiovascular system...
  60. ncbi Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands
    Alan M Warshawsky
    Eli Lilly and Co, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 16:6328-33. 2006
    ..Several compounds in this series have demonstrated potent plasma glucose and triglyceride lowering capability in rodent models of type 2 diabetes...
  61. ncbi Oxidative stress influences cholesterol efflux in THP-1 macrophages: role of ATP-binding cassette A1 and nuclear factors
    Valérie Marcil
    Centre de Recherche, CHU Sainte Justine, Universite de Montreal, 3175, Cote Ste Catherine, Montreal Quebec, Canada H3T 1C5
    Cardiovasc Res 72:473-82. 2006
    ..Our aim was to characterize the effects of oxidative stress on key receptors of macrophage cholesterol homeostasis, on the nuclear transcription factors PPAR and LXR regulating their expression, and on macrophage cholesterol handling...
  62. ncbi The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis
    Sarah Hummasti
    Howard Hughes Medical Institute, Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California 90095 1662, USA
    Mol Endocrinol 20:1261-75. 2006
    ..A more detailed understanding of the mechanisms by which the individual PPARs differentially regulate gene expression should aid in the design of more effective drugs, including tissue- and target gene-selective PPAR modulators...
  63. ncbi Nuclear hormone receptors and intestinal inflammation
    Gary D Wu
    Gastroenterology 133:1068. 2007
  64. ncbi 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility
    Brad R Henke
    Metabolic and Viral Diseases Drug Discovery Research, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Prog Med Chem 42:1-53. 2004
  65. ncbi PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    W Ahmed
    Cardiovascular Division, Harvard Medical School, Brigham and Women s Hospital, Boston, MA, USA
    J Intern Med 262:184-98. 2007
    ....
  66. ncbi PPARs special issue: anchoring the present to explore the future
    Beatrice Desvergne
    University of Lausanne, Genopode, 1015 Lausanne, Switzerland
    Biochim Biophys Acta 1771:913-4. 2007
  67. ncbi Gender and genetic differences in bladder smooth muscle PPAR mRNA in a porcine model of the metabolic syndrome
    Heather M Mattern
    Department of Medical Pharmacology and Physiology, University of Missouri, MA415 Medical Sciences Building, Columbia, MO 65212, USA
    Mol Cell Biochem 302:43-9. 2007
    ..We conclude that PPAR profiles in BSM may contribute to the susceptibility of BSM to lipotoxicity in the metabolic syndrome...
  68. ncbi PPAR agonists: multimodal drugs for the treatment of type-2 diabetes
    Barbara Gross
    Institut Pasteur de Lille, 1 rue du Prof Calmette, Lille, F 59019, France
    Best Pract Res Clin Endocrinol Metab 21:687-710. 2007
    ..This chapter focuses on the PPAR agonists currently used in the clinic, as well as on the discovery and development of the next generation of PPAR agonists...
  69. ncbi Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid
    Yoshimitsu Yamazaki
    Institute for Biological Resources and Functions, National Institute of Advanced Industrial Science and Technology, 1 1 1 Higashi, Tsukuba, Ibaraki 305 8566, Japan
    Life Sci 82:290-300. 2008
    ....
  70. pmc Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer
    Aruna Jahoor
    Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, 3601 4th St, Lubbock, TX 79430, USA
    J Bacteriol 190:4408-15. 2008
    ..These data identify PPARbeta/delta and PPARgamma as putative mammalian 3OC(12)-HSL receptors and suggest that PPARgamma agonists may be employed as anti-inflammatory therapeutics for P. aeruginosa infections...
  71. ncbi In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886)
    Andrea Biserni
    Center of Excellence on Neurodegenerative Diseases, Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy
    Mol Pharmacol 73:1434-43. 2008
    ..The results of this study, demonstrating the usefulness of reporter mice, may open new avenues for the development of innovative drugs for cardiovascular, endocrine, neural, and skeletal systems characterized by limited side effects...
  72. ncbi Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors alpha and gamma and of retinoid X receptors
    E N Posokhova
    Institute of Internal Medicine, Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russia
    Biochemistry (Mosc) 73:296-304. 2008
    The effects of peroxisome proliferator activated receptors alpha and gamma (PPAR-alpha and PPAR-gamma) and retinoid X receptor (RXR) agonists upon synthesis and accumulation of lipids in murine C57Bl macrophages during inflammation ..
  73. ncbi Effect of medium- and long-chain fatty acid diets on PPAR and SREBP-1 expression and glucose homeostasis in ACBP-overexpressing transgenic rats
    S Oikari
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute for Molecular Sciences, Kuopio, Finland
    Acta Physiol (Oxf) 194:57-65. 2008
    ..As the physiological relevance of ACBP in the regulation of lipid metabolism under high fat diets is unclear, we investigated the influence of such diets on the metabolic responses in ACBP-overexpressing rats...
  74. ncbi A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis
    Andrea V Leisewitz
    Facultad de Ciencias Biologicas, Department of Cellular and Molecular Biology, Centro de Regulación Celular y Patología CRCP, Millennium Institute for Fundamental and Applied Biology, P Universidad Catolica de Chile, Alameda, Santiago, Chile
    J Cell Physiol 217:367-76. 2008
    b>Peroxisome proliferator activated receptors (PPARs, alpha, beta/delta, gamma) control lipid homeostasis and differentiation in various tissues and tumor cells...
  75. ncbi Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol
    Furong Wang
    Provincial Hospital affiliated to Shandong University, Jinan, Shandong 250021, China
    Can J Physiol Pharmacol 86:465-71. 2008
    ..In conclusion, mRNA expression of PPARs is tissue-specific in diabetes and may be differently affected by cilostazol, possibly because of its tissue-specific effects on cAMP content...
  76. ncbi Novel oxazole containing phenylpropane derivatives as peroxisome proliferator activated receptor agonists with hypolipidemic activity
    H Pingali
    Zydus Research Centre, Sarkhej Bavla N H 8A Moraiya, Ahmedabad, India
    Pharmazie 63:497-502. 2008
    ..Compounds 3c and 3d showed the desired predominant PPARalpha activity and excellent tryiglyceride reduction in vivo and were selected as lead compounds for further development as hypolipidemic agents...
  77. ncbi PPAR and LXR activators regulate ABCA12 expression in human keratinocytes
    Yan J Jiang
    Metabolism Section, Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education, University of California at San Francisco, San Francisco, California 94121, USA
    J Invest Dermatol 128:104-9. 2008
    ..Together, our data demonstrate that PPAR and LXR activators increase ABCA12 expression, providing an additional mechanism by which PPAR and LXR activators promote epidermal permeability barrier homeostasis...
  78. ncbi The next generation of PPAR drugs: do we have the tools to find them?
    Barry G Shearer
    GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Biochim Biophys Acta 1771:1082-93. 2007
    ..In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs...
  79. ncbi Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas
    Jonathan Golledge
    Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland, Australia
    Stroke 38:1501-8. 2007
    ..We investigated the effect of peroxisome proliferator-activated receptor (PPAR) -alpha and -gamma ligands in acutely modifying tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in unstable carotid atheromas...
  80. ncbi Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines
    Elisa B Atarod
    Division of Pharmacology and Toxicology, College of Pharmacy, University of Texas at Austin, Austin, TX 78712 0125, USA
    Free Radic Biol Med 37:36-47. 2004
    ..These data also suggest that oxidant production induced by PPARalpha ligands originates in the mitochondria...
  81. ncbi Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives
    Raok Jeon
    College of Pharmacy, Sookmyung Women s University, Chungpa dong 2 Ka, Yongsan Ku, Seoul 140 742, Korea
    Arch Pharm Res 27:1099-105. 2004
    ..Most compounds tested were identified as potent PPARgamma agonists...
  82. ncbi Modulation of PPAR in aging, inflammation, and calorie restriction
    Bokyung Sung
    College of Pharmacy, Aging Tissue Bank, Pusan National University, Busan, Korea
    J Gerontol A Biol Sci Med Sci 59:997-1006. 2004
    ..Based on these findings, we conclude that the altered expression of PPARs may be due to increased oxidative stress with age, and that CR prevents these decreases through its antioxidative action...
  83. ncbi An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines
    Marina Maggiora
    Dipartimento di Medicina e Oncologia Sperimentale, Universita di Torino, Torino, Italy
    Int J Cancer 112:909-19. 2004
    ..In conclusion, CLA may be regarded as a component of the diet that exerts antineoplastic activity and its effect may be antiproliferative or pro-apoptotic...
  84. pmc Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus
    E Linda R Sheldrick
    Division of Animal Physiology, School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough LE12 5RD, UK
    Biochem J 406:175-83. 2007
    ..The results are consistent with the hypothesis that arachidonic acid acts via PPARalpha to increase PTGS2 levels in bovine endometrial stromal cells...
  85. ncbi Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease
    Liliane Michalik
    Center for Integrative Genomics, National Research Center Frontiers in Genetics, University of Lausanne, Genopode Building, CH 1015 Lausanne, Switzerland
    Biochim Biophys Acta 1771:991-8. 2007
    ..Due to their collective diverse functions in skin biology, PPARs represent a major research target for the understanding and treatment of many skin diseases, such as benign epidermal tumors, papillomas, acne vulgaris and psoriasis...
  86. ncbi Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets
    Cathrine M Holland
    Department of Pathology, University of Cambridge, The Rosie Hospital, Box 223, Level 2, Robinson Way, Cambridge CB2 2SW, United Kingdom
    Mol Cancer Ther 3:993-1001. 2004
    ..These results support further investigation of members of the PPAR/retinoid X receptor pathway as novel therapeutic targets in endometrial cancer...
  87. ncbi Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology
    Roberto Scatena
    Istituto di Biochimica e Biochimica Clinica, Universita Cattolica, Rome, Italy
    Eur J Pharmacol 567:50-8. 2007
    b>Peroxisome proliferator activated receptors (PPARs) are a class of nuclear receptors now actively investigated for their involvement in lipid and glucidic metabolism, immune regulation and cell differentiation...
  88. pmc Modulation of PPAR activity via phosphorylation
    Katherine A Burns
    Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis, Penn State University, University Park, PA 16802, USA
    Biochim Biophys Acta 1771:952-60. 2007
    ..The review will summarize the known PPAR kinases that directly act on these receptors, the sites affected and the result of this modification on receptor activity...
  89. ncbi PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells
    Shamilah Lachal
    Department of Surgery ARMC, University of Melbourne, Department of Surgery, Austin Health, Heidelberg, Victoria 3084, Australia
    Regul Pept 120:243-51. 2004
    ..These studies have revealed a relationship between PPARs and gastrin, two regulatory molecules implicated in the pathogenesis of CRC...
  90. ncbi Effects of cold stress on the messenger ribonucleic acid levels of peroxisome proliferator-activated receptor-{gamma} in spleen, thymus, and bursa of Fabricius of chickens
    J T Wang
    College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, P R China
    Poult Sci 88:2549-54. 2009
    ..The magnitude and direction of change in PPAR-gamma gene expression differs with the type of cold stress applied and also varies by tissue...
  91. ncbi [Effect of peroxisome proliferators activated receptor gamma and its ligand on airway mucus hypersecretion in rats]
    Wei Jia Liu
    Department of Respiratory Medicine, Sichuan University West China Hospital, Chengdu 610041, China
    Zhonghua Jie He He Hu Xi Za Zhi 32:282-6. 2009
    ..To explore the effect and the molecular mechanisms of peroxisome proliferators activated receptor gamma (PPAR-gamma) and its ligand on airway mucus hypersecretion...
  92. ncbi Peroxisomal beta-oxidation and steatohepatitis
    M S Rao
    Department of Pathology, Northwestern University Medical School, Chicago, Illinois, USA
    Semin Liver Dis 21:43-55. 2001
    ....
  93. ncbi Peroxisome proliferator-activated receptors, coactivators, and downstream targets
    C Qi
    Department of Pathology, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Cell Biochem Biophys 32:187-204. 2000
    ....
  94. ncbi Relationship between different stages of the corpus luteum and the expression of the peroxisome proliferator-activated receptor gamma protein in bovine large lutein cells
    T Viergutz
    Research Institute for the Biology of Farm Animals, Dummerstorf, Germany
    J Reprod Fertil 118:153-61. 2000
    ....
  95. ncbi Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes
    A Ibabe
    Biologia Zelularra eta Histologia Laborategia, Zoologia eta Animali Biologia Zelularra Saila, Zientzia eta Teknologia Fakultatea, Euskal Herriko Unibertsitatea Universidad del País Vasco, 644 PK, Bilbao E 48080, Basque Country, Spain
    Toxicol In Vitro 19:725-35. 2005
    ..Further studies are needed to identify how the expression of different PPAR subtypes is regulated and to elucidate the implication of PPAR subtypes in zebrafish cell functions...
  96. ncbi Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases
    N Latruffe
    LBMC, University of Burgundy, 21000 Dijon, France
    Biochem Pharmacol 60:1027-32. 2000
    ..Eur J Biochem 230:316-321, 1995). From all these findings, PPAR alpha and kinases appear to play an important role in lipid homeostasis...
  97. pmc Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009
    ..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)...
  98. ncbi Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin
    Fumiki Oana
    Division of Discovery Research, Kissei Pharmaceutical Co Ltd, 4365 1, Hotaka, Nagano 399 8304, Japan
    Metabolism 54:995-1001. 2005
    ....
  99. ncbi Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresso
    J W Lawrence
    Department of Safety Assessment, Merck Research Laboratories, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    J Biol Chem 276:31521-7. 2001
    ..These results suggest that other factors besides PPAR alpha levels determine the species-specific response of human and rat hepatocytes to the induction of PP...
  100. pmc Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
    A Vidal-Puig
    Department of Medicine, Beth Israel Hospital, Boston, Massachusetts 02215, USA
    J Clin Invest 97:2553-61. 1996
    ..These findings demonstrate in vivo modulation of PPAR gamma mRNA levels over a fourfold range and provide an additional level of regulation for the control of adipocyte development and function...
  101. ncbi Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression
    L J Kelly
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    Endocrinology 139:4920-7. 1998
    ..PPAR alpha activation in mice is sufficient to induce liver UCP-2 expression...

Research Grants77

  1. Effect of PPARy Ligands on Alcohol-Induced Alveolar Macrophage Oxidative Stress
    Samantha M Yeligar; Fiscal Year: 2013
    ..Thus, this K99/R00 application provides an excellent opportunity to advance the career of a talented and promising investigator. ..
  2. MOLECULAR BASIS OF INSULIN RESISTANCE
    Maureen J Charron; Fiscal Year: 2010
    ..Results of these studies may yield new information for setting guidelines for pregnant and lactating women that may protect offspring from enhanced susceptibility to these metabolic diseases. ..
  3. Neuroprotection and Myelin Repair Mechanisms in Multiple Sclerosis
    Inderjit Singh; Fiscal Year: 2013
    ....
  4. Mechanisms and Consequences of Reduced PPAR gamma in Pulmonary Hypertension
    C Michael Hart; Fiscal Year: 2013
    ..The results of this proposal can thereby define novel and effective therapeutic strategies to regulate programs of gene expression involved in PH pathogenesis. ..
  5. Lipid Binding Proteins in Obesity and Diabetes Syndromes
    David A Bernlohr; Fiscal Year: 2013
    ..3. Evaluate the interaction of FABPs with LTA4 and LTA4 metabolizing enzymes. 4. Examine the effects of leukotrienes on macrophage and adipocyte signal transduction and cytokine synthesis. ..
  6. Role of GDNF in the regulation of hepatic steatosis
    SHANTHI K SRINIVASAN; Fiscal Year: 2013
    ..Identification of new therapies for hepatic steatosis will directly benefit the veteran population. Taken together our data from this proposal may provide novel targets for the treatment or prevention of hepatic steatosis. ..
  7. Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
    RONALD JAY KOENIG; Fiscal Year: 2013
    ..The importance of PPFP functional domains on xenograft tumor formation and metastases will be assessed with DoxyPPFP cell lines expressing mutant PPFPs (for example, mutation of either the PAX8 or PPARg DNA binding domain). ..
  8. Regulation of insulins by the Rhox5 homeobox gene supports spermatogenesis
    James Maclean; Fiscal Year: 2009
    ..Thus, the characterization of Rhox5-null mice may also be useful as a model system for understanding human fertility problems. ..
  9. Transcriptional Regulation of Natriuetic Sensitivity in Diabetes Mellitus
    PATIENCE O OBIH; Fiscal Year: 2012
    ..The information obtained from this study will enable the Principal Investigator to apply for competitive external grants like R01 in the future. ..
  10. Lipid Binding Proteins in Obesity and Diabetes Syndromes
    David A Bernlohr; Fiscal Year: 2011
    ..3. Assess the role of fatty acid binding proteins in leukotriene biosynthesis. 4. Examine the effect of leukotrienes on adipocyte and macrophage signal transduction and metabolism. ..
  11. Biomarkers to Assess Selenium Chemoprevention for NSCLC
    Steven A Belinsky; Fiscal Year: 2012
    ..Studies will also assess whether these same biomarkers can predict cancer recurrence. Finally, a cocktail of agents with minimal side effects is being evaluated that could ultimately be used in the prevention of lung cancer in humans. ..
  12. Liver disease in CF: CFTR controls innate immunity in biliary epithelium
    Mario Strazzabosco; Fiscal Year: 2013
    ....
  13. Molecular Mechanism of Acrolein-Induced Vascular Toxicity: Role of PPAR gamma and
    Zivar Yousefipour; Fiscal Year: 2013
    ....
  14. Beta-cell Compensation in Partial Pancreatectomy Mice
    JOHN L LEAHY; Fiscal Year: 2013
    ..abstract_text> ..
  15. Repression of PPARgamma-2 by Glucocorticoid-Induced Leucine Zipper
    Xing Ming Shi; Fiscal Year: 2012
    ..Thus, understanding how PPAR(2 can be negatively regulated, a focus of this study, may lead to new therapies for treating osteoporosis and obesity. ..
  16. Nuclear Receptor Coactivator Functions and Mechanisms
    Robert G Roeder; Fiscal Year: 2013
    ..By identification of new factors and mechanisms, and thus of novel therapeutic targets, these studies will have important implications for the control of obesity and muscle dystrophy. ..
  17. Chronic Granulomatous Lung Inflammation Elicited by Carbon Nanotubes
    Mary Jane Thomassen; Fiscal Year: 2013
    ..In summary, this unique investigation of MWCNT-elicited granulomatous lung disease is well suited for student participation in an area with environmental impact on human disease. ..
  18. Novel PPAR-Independent Peroxisome Proliferators for Type 2 Diabetes
    LIDIA NIEROBISZ; Fiscal Year: 2011
    ..We propose to develop novel PPAR-Independent Peroxisome Proliferators for Type 2 Diabetes to address this market need. ..
  19. PREVENTION OF QUINONE TOXICITY AND MUTAGENICITY
    ANIL KUMAR JAISWAL; Fiscal Year: 2013
    ..The studies are clinically relevant since a significant number of individuals are deficient in NQO1 and NQO2, or both due to mutations/gene alterations. ..
  20. Synergistic Roles of Adiponectin & PPARgamma in Beta-Cell Survival/Proliferation
    William L Holland; Fiscal Year: 2010
    ..The PANIC ATTAC mouse allows the unique opportunity to evaluate beta cell regeneration following the cell specific and titratable induction of apoptosis. ..
  21. Inflammation and Immunosuppression in Lung Cancer
    Cong Yan; Fiscal Year: 2013
    ..Accomplishment of the proposed studies will elucidate the molecular mechanism by which the LAL/hormonal ligands/PPAR? axis controls anti-tumor adaptive immunity and pave the way for novel immunotherapy of lung cancer. ..
  22. Nitrated fatty acids/PPARgamma in the control of renal and vascular functions
    Tianxin Yang; Fiscal Year: 2012
    ..The current proposal is expected to provide new information for required for development of more effective therapies for the human disease. ..
  23. Lipid Metabolism and Steatosis in Liver
    Amrita Kamat; Fiscal Year: 2013
    ..The study is expected to have an important impact by defining new molecular targets for the prevention and/or treatment of NAFLD and its complications. ..
  24. Mitochondrial Protection Within Chronically Ischemic Myocardium
    Edward O McFalls; Fiscal Year: 2010
    ..Using this model, we propose that a class of drugs used in diabetic patients that has been associated with heart failure exacerbations, alters the mitochondrial energy production in a similar way. ..
  25. INSULIN ACTION IN MUSCLE AND FAT CELLS
    JAMES CARLTON GARRISON; Fiscal Year: 2010
    ..Lentivirus will be used to overexpress rictor or to express shRNA to knockdown rictor in 3T3-L1 adipocytes. To investigate mTORC2 function in vivo, we propose to knockout rictor in adipocytes and skeletal muscle of mice. ..
  26. Lipocalin 2 in Inflammation and Metabolic Control
    Xiaoli Chen; Fiscal Year: 2012
    ..The knowledge obtained will provide the key to solve the molecular puzzle of obesity and lead to the identification of novel strategies for preventive and therapeutic interventions. ..
  27. Translating human PPARy binding regions to gene regulation and metabolic disease
    RAYMOND EDWARD SOCCIO; Fiscal Year: 2013
    ..Soccio from the mentored to the independent phase of this 5 year career development award. These studies of the human PPAR cistrome have potentially great translational relevance to the epidemics of diabetes and obesity. . ..
  28. Harness Germinal Matrix Hemorrhage
    John H Zhang; Fiscal Year: 2013
    ..The long-term goals of this proposal are to provide non-invasive therapeutic approaches for GMH patients. ..
  29. Mitoenergetic Failure in Brain Aging
    Gregory J Brewer; Fiscal Year: 2013
    ..S. who will constitute 23% of the population in 2040, 70 million people. 13 million of these people are expected to have Alzheimer disease with expected health care costs of $250 billion. ..
  30. The Role of PPAR Gamma in Fat-Resident Regulatory T Cells and Glucose Homeostasis
    SAGAR PRADEEP BAPAT; Fiscal Year: 2013
    ..Taken together, these studies will systematically characterize the role of PPAR! in fTregs and illuminate the role of fTregs in the pathogenesis of obesity-related type-2 diabetes. ..
  31. PPAR gamma Agonists for Lung Cancer Chemoprevention
    Robert Keith; Fiscal Year: 2013
    ..Our results will lead to a better understanding of the early stages of lung cancer and may lead to future human chemoprevention trials. ..
  32. Effect of constitutive Type 2 NF-kB on adipogenesis
    LOTUS KYI LOO; Fiscal Year: 2010
    ....
  33. Prostacyclin Synthase and Receptors in Pulmonary Arterial Hypertension
    Mark W Geraci; Fiscal Year: 2011
    ....
  34. A novel axis regulates adipocyte plasticity
    Sean Hartig; Fiscal Year: 2013
    ..I anticipate that my studies will provide new clues into the complex regulatory networks controlling energy balance in fat cells. If my hypothesis is true, the Ubc9/miR-30a axis might be exploited in novel therapies to manage T2DM. ..
  35. Rev-ERBa Regulates Mitochondrial Biogenesis, Adiposity, and Insulin Action
    Thomas H Reynolds; Fiscal Year: 2010
    ..The overall goal of this proposal is to learn more about how Rev-ERBa reduces adiposity and enhances insulin action. ..
  36. The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog
    Albert R La Spada; Fiscal Year: 2013
    ....
  37. Roles for Phospholipase D2 in metabolism and cardiovascular homeostasis
    ROCHELLE NELSON; Fiscal Year: 2013
    ..These studies will also provide information necessary for new pharmacological targets aimed at the prevention of cardiovascular disease risk factors including hypertension and atherosclerosis. ..
  38. PPARgamma and PPARgamma agonists in septic shock
    Basilia Zingarelli; Fiscal Year: 2013
    ..These studies may have an impact in developing novel therapies to decrease sepsis morbidity and mortality. ..
  39. Pathogenic Mechanisms of Fatty Liver Disease
    Mohammad S Siddiqui; Fiscal Year: 2011
    ....
  40. Effects of Dietary Fat on Contractile and Mitochondrial Function in Heart Failure
    Margaret P Chandler; Fiscal Year: 2010
    ..involved in a cardio-protective effect of a high saturated fat diet may include activation of peroxisome proliferator activated receptors (PPAR) and their co-activator PPAR gamma co-activator-1 (PGC-1) that operate to stimulate ..
  41. Connection of Mineral and Energy Metabolism by the Nuclear Receptor PPAR-gamma
    Yihong Wan; Fiscal Year: 2013
    ..Therefore, this investigation will significantly impact the broader scientific, clinical, and patient community. ..
  42. High-Content Screening for Peroxisome Biogenesis for Type-II Diabetes.
    JONATHAN ZACHARY SEXTON; Fiscal Year: 2013
    ..We have validated a known therapeutic compound in mice as a potent activator in our assay to use for compound screening and secondary/orthogonal assay development. ..
  43. Virtual Screening Development to Complement Experimental Screening for PPAR Modul
    Stephanie N Lewis; Fiscal Year: 2012
    ....
  44. Lipid Activated Nuclear Receptors in Age-Related Macular Degeneration
    Goldis Malek; Fiscal Year: 2013
    ..Understanding the mechanisms underlying deposit formation and identifying signaling pathways key to disease initiation and progression will open up new avenues for therapeutic strategies in early 'dry'AMD. ..
  45. Sleep Apnea and Dysregulation of Lipid Metabolism
    Vsevolod Y Polotsky; Fiscal Year: 2013
    ..abstract_text> ..
  46. Abdominal Adipose Tissue Inflammation
    Peter S Tobias; Fiscal Year: 2013
    ..Collectively, these studies will provide key insight into an extreme atherosclerosis pathology linked to systemic inflammation resulting from chronic exposure to tissue injury, infectious agents and pathogens. ..
  47. Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition
    Deanna L Kroetz; Fiscal Year: 2013
    ..The studies proposed in this application will explore a novel pathway for protection against acute kidney injury which exploits an abundant renal fatty acid epoxide with established roles in inflammation and apoptosis. ..
  48. Regulation and Function of the Rhox5 Homeobox Gene
    MILES FROME WILKINSON; Fiscal Year: 2013
    ..In addition, Rhox5 is regulated by a novel transcriptional mechanism that may significantly add to our understanding of gene regulation in general. ..
  49. PPAR delta functions in liver
    Chih Hao Lee; Fiscal Year: 2013
    ..The study is expected to lead to new areas of research and to have important clinical implication, as this novel lipid signaling may serve as a marker and a therapeutic target of metabolic diseases. ..
  50. Modulation of PPAR-gamma phosphorylation at S273 regulates insulin sensitivity
    ALEXANDER BANKS; Fiscal Year: 2013
    ....
  51. Regulation of glucose homeostasis by C/EBPB
    Jacob E Friedman; Fiscal Year: 2010
    ....
  52. Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance
    Raju C Reddy; Fiscal Year: 2013
    ..It would also establish the feasibility of an innovative approach to restoring therapeutic glucocorticoid sensitivity, thereby promoting PPAR-g-glucocorticoid synergy, in COPD and potentially in other steroid-resistant diseases. ..
  53. Glycerolipid synthesis in liver
    ROSALIND ANNE COLEMAN; Fiscal Year: 2013
    ..These studies, using unique mouse models and innovative approaches, will address major gaps in our understanding of why excess tissue TAG is intimately associated with insulin resistance. ..
  54. Adiponectin Actions on the Monocyte to Reduce Atherosclerosis
    Rajendra K Tangirala; Fiscal Year: 2013
    ..abstract_text> ..
  55. Cardiac metabolism and heart failure
    Rong Tian; Fiscal Year: 2010
    ..Results from the study will provide a basis for optimizing cardiac metabolism as part of the treatment strategy for heart failure. This is particularly important for patients with metabolic disorders such as obesity or diabetes. ..
  56. CNS PPAR gamma and energy homeostasis
    HEIDI E KOCALIS; Fiscal Year: 2011
    ..Obesity is accompanied by CNS insulin and leptin resistance and NF-xB like signaling. Peroxisome proliferator activated receptors (PPAR) are nuclear receptors that are the target of drugs used clinically to treat diabetes and ..
  57. Cytochrome P4501B1 and basal liver PPARa activity
    COLIN ROBERT JEFCOATE; Fiscal Year: 2013
    ..Serum markers applicable to clinical studies will be used in probing these liver changes. ..
  58. Gender Effects on Remodeling of Lipid and Sarcomere Dynamics in Hypertrophy
    E Douglas Lewandowski; Fiscal Year: 2013
    ....
  59. The Role of Nuclear Receptor PPARbeta in the Regulation of Muscle Fuel Metabolism
    EMILY YVONNE SMITH; Fiscal Year: 2013
    ..In the long-term, we seek to use this information to identify novel therapeutic targets aimed at the prevention and treatment of obesity-associated diseases. ..
  60. APOLIPOPROTEIN GENES AND ATHEROGENESIS IN ANIMALS
    Nobuyo Maeda; Fiscal Year: 2012
    ..Using mouse genetics as a tool, we aim to determine how some common human genetic differences affect atherosclerosis and how the genetic effects are influenced by being overweight and by other common gene variants. ..
  61. Mechanisms of Inflammatory Lung Disease in Neonates
    BARRY I WEINBERGER; Fiscal Year: 2010
    ..The proposed studies will address this need, suggesting ways to decrease the incidence of BPD and other adverse outcomes that result from inflammation in newborns. ..
  62. Effects of Ethanol on Insulin Signaling in the Brain
    Suzanne M de la Monte; Fiscal Year: 2013
    ..The experimental design is translational because it utilizes a therapeutic strategy that realistically could be applied to humans. ..
  63. Echium Oil Modulates Macrophage Inflammation by Promoting Alternative Activation
    AMANDA WIBLEY; Fiscal Year: 2010
    ....
  64. MOLECULAR BASIS OF HIV LIPODYSTROPHY: ROLE OF VPR
    Ashok Balasubramanyam; Fiscal Year: 2003
    ....
  65. ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS
    Gary Gilkeson; Fiscal Year: 2005
    ..As agonists of PPAR gamma (the thiazolidinediones) are already approved for human use, insight gained from these studies can be quickly translated into human trials. ..
  66. PPAR- GAMMA LIGANDS IN ULCERATIVE COLITIS
    James Lewis; Fiscal Year: 2001
    ..It is expected that in the final 6 months of this project, the investigators will organize a multicenter randomized controlled trial of troglitazone in the treatment of mild to moderate ulcerative colitis. ..
  67. Role of PPARbeta in colon carcinogenesis
    Jeffrey Peters; Fiscal Year: 2007
    ..abstract_text> ..
  68. Tumor Suppression Through Oxidized Glycerophosphocholines
    Raymond L Konger; Fiscal Year: 2010
    ..The proposed studies will determine whether tumor promoters induce ox-GPCs that serve a protective function in neoplastic development by activating growth-inhibitory PAF-R and/or PPAR?. ..
  69. The function(s) and regulation of PPARs in the ovary
    Carolyn Komar; Fiscal Year: 2003
    ....
  70. PEROXISOME PROLIFERATORS AND THE CELL CYCLE
    JANE ISHMAEL; Fiscal Year: 2002
    ..In general it is hoped that these studies will increase our understanding of the relationship between cell proliferation and hepatocarcinogenesis induced by nongenotoxic carcinogens. ..
  71. Role of PPAR-gamma Isoforms in Regulation of Macrophage apoE & LPL Expression
    Jheem Medh; Fiscal Year: 2006
    ..Information about ligand specificities of individual PPAR-g protein isoforms and their specific gene targets will allow for the selective induction of desirable genes and repression of harmful ones. [unreadable] [unreadable] [unreadable]..
  72. Association of PPAR gamma ligands & colonic neoplasia
    James Lewis; Fiscal Year: 2006
    ..Our results will allow us to translate the existing in vitro and in vivo observations to the intact human colon and could lead to further chemoprevention strategies. ..
  73. Pioglitazone Therapy for Endocrine and Exocrine Disease in Alcoholic Pancreatitis
    MATTHEW DIMAGNO; Fiscal Year: 2009
    ....
  74. Chemoprevention of Pituitary Corticotroph Tumors
    Anthony Heaney; Fiscal Year: 2006
    ..Our ultimate goal is to develop a rationale for clinical application of these PPAR-gamma ligands as a novel medical therapy in Cushing's disease. ..
  75. Microparticles as Messengers of Communication Between Blood and Vascular Cells
    Richard P Phipps; Fiscal Year: 2010
    ..Understanding this new way of cell to cell communication will lead to new methods and biomarkers to detect disease and to new ways of delivering therapy to reduce the consequences of diabetes and other diseases. ..
  76. Structural and functional studies of the nuclear receptor PPARgamma
    H Eric Xu; Fiscal Year: 2010
    ....
  77. The impact of PPAR-gamma and estrogen receptor crosstalk on insulin action
    Andrea Hevener; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..